- Home
- UROY vs ACIU Comparison
UROY vs ACIU Comparison
Compare UROY & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- ACIU
- Stock Information
- Founded
- UROY 2017
- ACIU 2003
- Country
- UROY Canada
- ACIU Switzerland
- Employees
- UROY N/A
- ACIU N/A
- Industry
- UROY
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- UROY
- ACIU Health Care
- Exchange
- UROY Nasdaq
- ACIU Nasdaq
- Market Cap
- UROY 229.9M
- ACIU 247.4M
- IPO Year
- UROY N/A
- ACIU 2016
- Fundamental
- Price
- UROY $1.85
- ACIU $1.64
- Analyst Decision
- UROY Strong Buy
- ACIU Strong Buy
- Analyst Count
- UROY 2
- ACIU 2
- Target Price
- UROY $4.00
- ACIU $12.00
- AVG Volume (30 Days)
- UROY 3.4M
- ACIU 176.4K
- Earning Date
- UROY 03-06-2025
- ACIU 05-12-2025
- Dividend Yield
- UROY N/A
- ACIU N/A
- EPS Growth
- UROY N/A
- ACIU N/A
- EPS
- UROY N/A
- ACIU N/A
- Revenue
- UROY $15,984,827.00
- ACIU $30,136,397.00
- Revenue This Year
- UROY N/A
- ACIU N/A
- Revenue Next Year
- UROY $6.55
- ACIU $676.94
- P/E Ratio
- UROY $339.12
- ACIU N/A
- Revenue Growth
- UROY N/A
- ACIU 84.51
- 52 Week Low
- UROY $1.43
- ACIU $1.43
- 52 Week High
- UROY $3.12
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- UROY 54.49
- ACIU 41.18
- Support Level
- UROY $1.65
- ACIU $1.45
- Resistance Level
- UROY $1.89
- ACIU $1.68
- Average True Range (ATR)
- UROY 0.13
- ACIU 0.10
- MACD
- UROY 0.03
- ACIU 0.04
- Stochastic Oscillator
- UROY 91.30
- ACIU 65.63
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.